Analysts Warn Medicare Drug Price Controls May Raise Long-Term Costs
If the analysts' projections hold, the Inflation Reduction Act's drug pricing provisions could produce outcomes that conflict with their stated cost-reduction goals, a tension Congress has not yet...
Analysts have warned that Medicare drug price negotiation controls established under the Inflation Reduction Act of 2022 could restrict patient access to care and drive up pharmaceutical costs over time, according to reporting by the Daily Caller published August 22, 2026. The Inflation Reduction Act (Public Law 117-169), signed by President Biden on August 16, 2022, authorized the Department of Health and Human Services to negotiate prices directly with drug manufacturers for a defined set of Medicare Part D and Part B drugs, beginning with ten drugs in 2026.
The law's price negotiation mechanism requires manufacturers to either accept a negotiated Maximum Fair Price or face an escalating excise tax on U.S. sales of the drug in question, starting at 65 percent and rising to 95 percent, as specified in IRA Section 1194. Critics, including analysts cited in the Daily Caller report, argue this structure could discourage investment in new drug development and reduce the number of treatments available to Medicare beneficiaries over time.
Proponents of the law, including the Congressional Budget Office in its August 2022 cost estimate of the Inflation Reduction Act, projected the drug negotiation provisions would reduce federal deficits by approximately $101.7 billion over the 2022 to 2031 window. The CBO score did not model long-term effects on pharmaceutical innovation or patient access beyond the ten-year budget window.
The Centers for Medicare and Medicaid Services completed its first round of price negotiations in August 2024, reaching agreements with manufacturers on ten drugs including Eliquis, Jardiance, and Xarelto, as disclosed in CMS public announcements at that time. The negotiated prices take effect January 1, 2026, per the IRA's statutory timeline.
What remains unknown is the degree to which the negotiated prices have affected manufacturer research and development spending or pipeline decisions since taking effect in January 2026. Pharmaceutical company annual reports filed with the Securities and Exchange Commission, specifically 10-K filings from affected manufacturers for fiscal year 2025 and 2026, would be the primary public record to consult for data on any changes in R and D expenditure attributed to the IRA pricing provisions.